Equities
Health CareMedical Equipment and Services
  • Price (USD)171.80
  • Today's Change2.67 / 1.58%
  • Shares traded222.99k
  • 1 Year change+85.44%
  • Beta0.9939
Data delayed at least 15 minutes, as of Nov 22 2024 16:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Masimo Corporation is a global technology company that develops and produces a range of monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. The Company's segments include Healthcare and Non-healthcare. Its Healthcare segment develops, manufactures and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. The Company's measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry and advanced rainbow Pulse CO-Oximetry parameters. The Company's Non-healthcare business develops, manufactures, markets, sells home sound integration technologies and accessories, along with licensing complete high performance in-vehicle audio systems under consumer brands, such as Bowers & Wilkins, Denon, Marantz, HEOS, Classe, Polk Audio, Boston Acoustics, and Definitive Technology.

  • Revenue in USD (TTM)2.04bn
  • Net income in USD78.60m
  • Incorporated1996
  • Employees3.80k
  • Location
    Masimo Corp52 DiscoveryIRVINE 92618United StatesUSA
  • Phone+1 (949) 297-7000
  • Fax+1 (949) 297-7499
  • Websitehttps://www.masimo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Procept Biorobotics Corp199.84m-100.06m5.11bn626.00--20.42--25.55-1.95-1.953.894.630.50261.833.86319,238.00-25.16---28.58--57.39---50.07--5.07--0.1758--81.55---21.51------
Inspire Medical Systems Inc755.59m33.05m5.58bn1.01k171.118.01146.817.381.091.0925.1523.251.052.469.37747,372.904.60-11.275.12-12.6084.7784.474.37-13.576.94--0.00--53.1965.3252.87--148.37--
Stevanato Group SpA1.15bn120.12m5.94bn5.64k43.863.8729.385.190.44730.44734.265.070.52842.752.66203,340.605.54--7.39--29.20--10.48--1.2148.530.2148--10.34--1.95------
Lantheus Holdings Inc1.50bn427.61m6.07bn834.0014.515.1512.394.066.026.0221.0916.970.83838.285.091,794,723.0023.956.6932.767.7364.7857.5628.579.021.56--0.3240.0038.6530.441,063.8651.8135.48--
Merit Medical Systems Inc1.33bn120.04m6.12bn6.95k51.454.6228.114.622.042.0422.5522.710.63342.297.41190,772.805.732.456.322.7746.8344.509.053.913.8231.880.36190.009.247.3326.7015.86-11.16--
Glaukos Corp360.35m-149.57m7.77bn907.00--11.61--21.55-2.96-2.967.0612.130.38431.697.53397,295.50-15.95-8.73-17.23-9.3576.6174.77-41.51-28.694.71-311.240.1591--11.2611.66-35.75--14.44--
Repligen Corp622.64m-17.13m7.94bn1.78k--3.94154.7212.75-0.3079-0.307911.0936.000.2331.575.29349,206.40-0.64114.38-0.70325.0350.3755.43-2.7515.918.76--0.20550.00-20.3126.91-77.6420.1324.99--
Bruker Corp3.24bn304.90m8.52bn9.71k27.114.7218.052.632.072.0721.8911.920.65271.515.73333,913.706.128.388.1411.4049.3149.859.3811.390.708526.830.55499.8117.149.3644.0318.9116.794.56
Teleflex Inc3.03bn238.01m8.85bn14.50k37.801.9817.532.935.045.0364.0196.500.4042.116.76208,677.503.185.863.466.4255.9954.437.8714.621.396.610.281815.846.573.97-1.4712.732.510.00
Masimo Corp2.04bn78.60m9.05bn3.80k116.326.1852.254.431.451.4537.7227.350.67151.775.52537,526.302.588.653.2310.3150.0557.303.8512.031.112.840.34560.000.604219.00-43.21-15.9631.06--
Bio Rad Laboratories Inc2.58bn-778.69m9.16bn8.03k--1.22--3.55-27.32-27.3290.77267.460.22941.495.61321,321.20-6.929.08-7.269.6054.4355.55-30.1841.974.520.26120.13830.00-4.673.1382.43--3.83--
Henry Schein, Inc.12.50bn314.00m9.20bn25.00k30.212.6415.540.73592.442.4496.8927.991.224.777.73499,960.002.976.094.8610.4431.5930.042.424.400.8176.230.3480.00-2.445.55-22.68-0.145621.27--
Penumbra Inc1.16bn34.55m9.23bn4.20k279.568.35151.567.930.86020.860229.7128.780.78971.046.08277,089.502.342.322.612.6165.7063.902.973.173.25--0.02180.0024.9518.934,643.1668.609.64--
Solventum Corp8.22bn720.00m12.03bn22.01k16.723.779.511.464.164.1647.4518.480.58313.937.19373,290.305.11--6.03--56.38--8.76--0.82685.020.7176--0.8241--0.2234------
Data as of Nov 22 2024. Currency figures normalised to Masimo Corp's reporting currency: US Dollar USD

Institutional shareholders

52.80%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 20245.71m10.68%
Politan Capital Management LPas of 30 Sep 20244.71m8.82%
The Vanguard Group, Inc.as of 30 Sep 20244.45m8.32%
BlackRock Fund Advisorsas of 30 Sep 20244.05m7.57%
BlackRock Advisors LLCas of 30 Sep 20241.77m3.31%
BlackRock Investment Management (UK) Ltd.as of 30 Sep 20241.72m3.21%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20241.53m2.85%
RTW Investments LPas of 30 Sep 20241.46m2.74%
SSgA Funds Management, Inc.as of 30 Sep 20241.44m2.69%
Westfield Capital Management Co. LPas of 30 Sep 20241.39m2.61%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.